Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma[J]. Expert Opin Pharmacother, 2009, 10(6): 983-995.Prichard M, Harris T, Williams ME, Densmore JJ. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother. 2009;...
James O. ArmitageAnnals of OncologyArmitage JO. Treatment strategies for patients with relapsed or refractory Hodgkin's disease. Ann Oncol 1995; 6:517-8.Armitage JO (1995) Treatment strategies for patients with relapsed or refractory Hodgkin s disease. Ann Oncol 6:517–518...
Among 311 patients with a relapse, 243 received second-line treatment: 44% received salvage chemotherapy, 20% received brentuximab vedotin (BV), and 36% received other treatment. In third-line treatment, BV was most commonly used (38%). ORR after second-line treatment was 47%. Two-year ...
In summary, the progress in the molecular understanding of PTCL has led to a more comprehensive therapeutic landscape that is rapidly evolving towards personalized treatment strategies and targeted therapies depending on specific histology and molecular profile. Current disease subtype-specific risk indices,...
There is no standard treatment for this group of patients. An important addition to the arsenal of new therapeutic possibilities is the development of the monoclonal antibody daratumumab directed against CD38, uniformly expressed on multiple myeloma cells. Rational combination strategies with daratumumab ...
EP: 11.Emerging Strategies in the Management of Relapsed/Refractory CLL Paolo Ghia, MD, PhD: In the area of immunochemotherapy, it depends which therapy you applied first. If you applied sCR [stringent complete response], then you couldn’t reapply sCR as the second treatment. Luckily the er...
Noopur S. Raje, MD, discusses the preliminary data with BCMA-directed treatment strategies in multiple myeloma.
Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group. The purpose of this study was to determine the therapeutic efficacy of different treatment strategies, namely chemother...
Team Blue vs Team Green: Treatment Strategies in Relapsed Refractory Multiple Myeloma : Episode 5 Patient Case: A 68-Year-Old Woman with Triple Class Exposed Relapsed Refractory Multiple Myeloma November 11, 2024 By Ehsan Malek, MD...
Optimal treatment for relapsing ovarian cancer in the treatment of relapsed ovarian cancer and highlight the most promising emerging therapeutics and strategies being employed in randomized clinical trials... RS Kristeleit - 《Annals of Oncology Official Journal of the European Society for Medical Oncolo...